Relaxed on Abivax: UC phase III cancer answer quells fretting

Source Summary

Wall Street breathed easier, and shares of Abivax SA found relief as further phase III data from the Abtect maintenance trial were disclosed with obefazimod in ulcerative colitis (UC).